| The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019 KB Tran, JJ Lang, K Compton, R Xu, AR Acheson, HJ Henrikson, ... The Lancet 400 (10352), 563-591, 2022 | 664 | 2022 |
| Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with … C Cremolini, C Antoniotti, D Rossini, S Lonardi, F Loupakis, F Pietrantonio, ... The Lancet Oncology 21 (4), 497-507, 2020 | 311 | 2020 |
| Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine G Numico, O Garrone, V Dongiovanni, N Silvestris, I Colantonio, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2005 | 256 | 2005 |
| Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples M Russano, A Napolitano, G Ribelli, M Iuliani, S Simonetti, F Citarella, ... Journal of Experimental & Clinical Cancer Research 39, 1-13, 2020 | 246 | 2020 |
| Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study JF Huang, J Shen, X Li, R Rengan, N Silvestris, M Wang, L Derosa, ... Annals of translational medicine 8 (7), 482, 2020 | 190 | 2020 |
| Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells A Azzariti, RM Iacobazzi, R Di Fonte, L Porcelli, R Gristina, P Favia, ... Scientific reports 9 (1), 4099, 2019 | 168 | 2019 |
| Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study D Santini, M Tampellini, B Vincenzi, T Ibrahim, C Ortega, V Virzi, ... Annals of oncology 23 (8), 2072-2077, 2012 | 162 | 2012 |
| Hospital admission of cancer patients: avoidable practice or necessary care? G Numico, A Cristofano, A Mozzicafreddo, OE Cursio, P Franco, ... PloS one 10 (3), e0120827, 2015 | 161 | 2015 |
| Current approaches for combination therapy of cancer: the role of immunogenic cell death Z Asadzadeh, E Safarzadeh, S Safaei, A Baradaran, A Mohammadi, ... Cancers 12 (4), 1047, 2020 | 147 | 2020 |
| Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? S Rizzo, G Bronte, D Fanale, L Corsini, N Silvestris, D Santini, G Gulotta, ... Cancer treatment reviews 36, S56-S61, 2010 | 140 | 2010 |
| The role of inflammatory cytokines and tumor associated macrophages (TAMs) in microenvironment of pancreatic cancer SF Valilou, M Keshavarz-Fathi, N Silvestris, A Argentiero, N Rezaei Cytokine & growth factor reviews 39, 46-61, 2018 | 126 | 2018 |
| Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma JS Chu, FJ Ge, B Zhang, Y Wang, N Silvestris, LJ Liu, CH Zhao, L Lin, ... Journal of Experimental & Clinical Cancer Research 32, 1-8, 2013 | 116 | 2013 |
| Dasatinib: an anti-tumour agent via Src inhibition A Gnoni, I Marech, N Silvestris, A Vacca, V Lorusso Current drug targets 12 (4), 563-578, 2011 | 115 | 2011 |
| Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target F De Vita, F Giuliani, N Silvestris, G Catalano, F Ciardiello, M Orditura Cancer treatment reviews 36, S11-S15, 2010 | 114 | 2010 |
| Immunotherapy for colorectal cancer: where are we heading? D Basile, SK Garattini, M Bonotto, E Ongaro, M Casagrande, M Cattaneo, ... Expert opinion on biological therapy 17 (6), 709-721, 2017 | 111 | 2017 |
| Combination of ipilimumab and nivolumab in cancers: from clinical practice to ongoing clinical trials O Kooshkaki, A Derakhshani, N Hosseinkhani, M Torabi, S Safaei, ... International journal of molecular sciences 21 (12), 4427, 2020 | 108 | 2020 |
| High density of tryptase‐positive mast cells in human colorectal cancer: a poor prognostic factor related to protease‐activated receptor 2 expression A Malfettone, N Silvestris, C Saponaro, G Ranieri, A Russo, S Caruso, ... Journal of cellular and molecular medicine 17 (8), 1025-1037, 2013 | 108 | 2013 |
| Adjuvant colon cancer chemotherapy: where we are and where we'll go L Lombardi, F Morelli, S Cinieri, D Santini, N Silvestris, N Fazio, L Orlando, ... Cancer treatment reviews 36, S34-S41, 2010 | 107 | 2010 |
| Neutrophils, crucial, or harmful immune cells involved in coronavirus infection: a bioinformatics study N Hemmat, A Derakhshani, H Bannazadeh Baghi, N Silvestris, ... Frontiers in genetics 11, 641, 2020 | 105 | 2020 |
| Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib AC Gardini, E Scarpi, L Faloppi, M Scartozzi, N Silvestris, D Santini, ... Oncotarget 7 (41), 67142, 2016 | 103 | 2016 |
daniele santiniprofessor in general pathologyPreverjeni e-poštni naslov na unicampus.it
